EPISODE · Jun 10, 2024 · 12 MIN
ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
from Two Onc Docs
This week’s episode will be discussing updates from the ASCO 2024 annual meeting starting with the practice changing LAURA trial: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated NSCLC: Primary results of the phase 3 LAURA study presented by Dr. Ramalingam.
NOW PLAYING
ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
No transcript for this episode yet
Similar Episodes
Feb 4, 2026 ·72m
Oct 22, 2025 ·38m
Oct 15, 2025 ·30m